NCT03725436View on ClinicalTrials.gov

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

January 24, 2019

Primary Completion Date

July 26, 2027

Study Completion Date

July 26, 2027

Conditions
Advanced Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Estrogen Receptor PositiveHER2/Neu NegativeMetastatic Malignant Solid NeoplasmPrognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Recurrent Breast CarcinomaTP53 wt AlleleUnresectable Malignant Solid Neoplasm
Interventions
DRUG

MDM2/MDMX Inhibitor ALRN-6924

Given IV

DRUG

Paclitaxel

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER